Pacira Biosciences Inc
NASDAQ:PCRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Merit Interactive Co Ltd
SZSE:300766
|
CN |
Pacira Biosciences Inc
Operating Expenses
Pacira Biosciences Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pacira Biosciences Inc
NASDAQ:PCRX
|
Operating Expenses
-$538m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-12%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Expenses
-$38.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Expenses
-$17.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Expenses
-$27.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Expenses
-$26.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Expenses
-$24.4B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-8%
|
|
Pacira Biosciences Inc
Glance View
Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Tampa, Florida and currently employs 697 full-time employees. The company went IPO on 2011-02-03. The firm is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, an extended-release drug delivery technology, that delivers bupivacaine over time for extended analgesia. Its ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain. Its iovera is a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
See Also
What is Pacira Biosciences Inc's Operating Expenses?
Operating Expenses
-538m
USD
Based on the financial report for Dec 31, 2025, Pacira Biosciences Inc's Operating Expenses amounts to -538m USD.
What is Pacira Biosciences Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-12%
Over the last year, the Operating Expenses growth was -26%. The average annual Operating Expenses growth rates for Pacira Biosciences Inc have been -11% over the past three years , -16% over the past five years , and -12% over the past ten years .
